RecruitingNot Applicable

Liquid Biopsy and Machine Learning for Early Colorectal Cancer, Adenomas, Lynch Cancers, and Residual Disease Detection

Italy1,200 participantsStarted 2024-01-01

Plain-language summary

This is an multicenter study that will test the diagnostic accuracy of a blood test (i.e., a liquid biopsy) for the diagnosis of colorectal cancer (CRC), advanced adenomas (AAs), as well as Lynch-syndrome associated cancers. Additionally, a pre-planned analysis will evaluate the use of this liquid biopsy as a tool for molecular residual disease monitoring purposes.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * All individuals included in the study need to have had a colonoscopy at the time of blood sampling. * Received standard diagnostic and staging (as necessary) procedures as per local guidelines, and at least one sample was drawn before receiving any curative-intent treatment. * Received standard pathological and endoscopic diagnosis and assessment for cohort assignment Exclusion Criteria: * Lack of informed consent * Inflammatory bowel disease

What they're measuring

Sensitivity

Timeframe: Through study completion, an average of 1 year

Trial details

NCT IDNCT07450612

SponsorSan Raffaele University

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2031-01-15

Contact for this trial

Giulia Martina Cavestro, MD, PhD

0226437217 cavestro.giuliamartina@hsr.it

View on ClinicalTrials.gov More Colorectal Cancer trials